National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 15109-15110 [05-5862]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 56 / Thursday, March 24, 2005 / Notices
research opportunities with the
inventors.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Cannula for Pressure Mediated Drug
Delivery
Stephen Wiener, Robert Hoyt, John
Deleonardis, Randal Clevenger, Robert
Lutz, Brian Safer (NHLBI)
PCT Application No. PCT/US99/11277
filed 21 May 1999, which published
as WO 99/59666 on 25 Nov 1999
(DHHS Reference No. E–196–1998/2–
PCT–01); U.S., Australian, Japanese,
and European rights pending
Licensing Contact: Michael
Shmilovich; 301/435–5019;
shmilovm@mail.nih.gov.
Available for licensing are methods
and devices for selective delivery of
therapeutic substances to specific
histologic or microanatomic areas of
organs (introduction of the therapeutic
substance into a hollow organ space
(such as an hepatobiliary duct or the
gallbladder lumen) at a controlled
pressure, volume or rate allows the
substance to reach a predetermined
cellular layer (such as the epithelium or
sub-epithelial space). The volume or
flow rate of the substance can be
controlled so that the intralumenal
pressure reaches a predetermined
threshold level beyond which
subsequent subepithehal delivery of the
substance occurs. Alternatively, a lower
pressure is selected that does not exceed
the threshold level, so that delivery
occurs substantially only to the
epithelial layer. Such site-specific
delivery of therapeutic agents permits
localized delivery of substances (for
example to the interstitial tissue of an
organ) in concentrations that may
otherwise produce systemic toxicity.
Occlusion of venous or lymphatic
drainage from the organ can also help
prevent systemic administration of
therapeutic substances, and increases
selective delivery to superficial
epithelial cellular layers. Delivery of
genetic vectors can also be better
targeted to cells where gene expression
is desired. The access device comprises
a cannula with a wall piercing tracar
within the lumen. Two axially spaced
inflatable balloons engage the wall
securing the cannula and sealing the
puncture site. A catheter equipped with
an occlusion balloon is guided through
the cannula to the location where the
therapeutic substance is to be delivered.
National Institutes of Health
Dated: March 17, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–5875 Filed 3–23–05; 8:45 am]
BILLING CODE 4140–01–P
VerDate jul<14>2003
15:04 Mar 23, 2005
Jkt 205001
Clinical Center; Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the NIH Advisory Board
for Clinical Research, March 28, 2005,
10 a.m. to March 28, 2005, 2 p.m.,
National Institutes of Health, Building
10, 10 Center Drive, Medical Board
Room 4–2551, Bethesda, MD, 20892
which was published in the Federal
Register on March 11, 2005, FR 70
12223.
The open session will occur from 10
a.m.–1 p.m. The closed session will
begin approximately at 1 p.m. and run
until 2 p.m. The meeting will be held
in the Clinical Center, Bldg. 10, Rm. 4–
2551, CRC Medical Board Room. The
meeting is partially closed to the public.
Dated: March 17, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5872 Filed 3–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Review of Research Projects (Cooperative
Agreements) (U01s).
Date: April 18, 2005.
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
15109
Contact Person: Keith A. Mintzer, PhD,
Scientific Review Administrator, Review
Branch, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute,
National Institutes of Health, 6701 Rockledge
Drive, Room 7186, MSC 7924, Bethesda, MD
20892, 301–435–0280.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: March 17, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5870 Filed 3–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Antidepressant
Therapy for Functional Dyspepsia.
Date: April 4, 2005.
Time: 3 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Adminstrator, Review
Branch, DEA, NIDDk, National Institutes of
Health, Room 777, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, Is38oz@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
E:\FR\FM\24MRN1.SGM
24MRN1
15110
Federal Register / Vol. 70, No. 56 / Thursday, March 24, 2005 / Notices
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Nuclear Receptors
Structure and Function.
Date: April 11, 2005.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Paul A. Rushing, PhD,
Scientific Review Administrator, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 747, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–8895, rushingp@extra.niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Loan Repayment.
Date: April 13, 2005.
Time: 1 p.m. to 3:30 p.m.
Agenda: To review and evaluate loan
repayment.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: D.G. Patel, PhD, Scientific
Review Administrator, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
755, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Beta Cell Biology
Consortium.
Date: April 14, 2005.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracry Boulevard, Bethesda, MD 20817.
Contact Person: Ned Feder, MD, Scientific
Review Administrator, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
778, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–8890,
federn@extra.niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
VerDate jul<14>2003
15:04 Mar 23, 2005
Jkt 205001
Dated: March 17, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5862 Filed 3–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel Fellowship Review.
Date: April 6, 2005.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Radisson Barcello, 2121 P Street,
NW., Washington, DC 20037.
Contact Person: Joann McConnell, PhD,
Scientific Review Administrator, Scientific
Review Branch, NIH/NINDS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529. (301)
496–5324, mcconnej@ninds.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Stroke Rehabilitation
Review.
Date: April 14, 2005.
Time: 10:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call.)
Contact Person: Richard Crosland, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research NINDS/NIH/DHHS/ Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, 301–
594–0635, rc218u@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Howard University SNRP
Review.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Date: April 19, 2005.
Time: 8 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Richard Crosland, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research NINDS/NIH/DHHS/ Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529. 301–
594–0635. rc218u@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Olfactory Receptors.
Date: April 20, 2005.
Time: 12:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call).
Contact Person: Richard D. Crosland, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, (301)
594–0635, rc218u@.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Ischemic Stroke Review.
Date: April 28, 2005.
Time: 10:30 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call).
Contact Person: Richard D. Crosland, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, (301)
594–0635. rc218u@.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: March 17, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5863 Filed 3–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 70, Number 56 (Thursday, March 24, 2005)]
[Notices]
[Pages 15109-15110]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-5862]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Antidepressant Therapy
for Functional Dyspepsia.
Date: April 4, 2005.
Time: 3 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference
Call).
Contact Person: Lakshmanan Sankaran, PhD, Scientific Review
Adminstrator, Review Branch, DEA, NIDDk, National Institutes of
Health, Room 777, 6707 Democracy Boulevard, Bethesda, MD 20892-5452,
(301) 594-7799, Is38oz@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing
[[Page 15110]]
limitations imposed by the review and funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Nuclear Receptors
Structure and Function.
Date: April 11, 2005.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference
Call).
Contact Person: Paul A. Rushing, PhD, Scientific Review
Administrator, Review Branch, DEA, NIDDK, National Institutes of
Health, Room 747, 6707 Democracy Boulevard, Bethesda, MD 20892-5452,
(301) 594-8895, rushingp@extra.niddk.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Loan Repayment.
Date: April 13, 2005.
Time: 1 p.m. to 3:30 p.m.
Agenda: To review and evaluate loan repayment.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference
Call).
Contact Person: D.G. Patel, PhD, Scientific Review
Administrator, Review Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy Boulevard, Bethesda, MD 20892-5452,
(301) 594-7682, pateldg@niddk.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Beta Cell Biology
Consortium.
Date: April 14, 2005.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracry Boulevard,
Bethesda, MD 20817.
Contact Person: Ned Feder, MD, Scientific Review Administrator,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 778,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8890,
federn@extra.niddk.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: March 17, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-5862 Filed 3-23-05; 8:45 am]
BILLING CODE 4140-01-M
